Kymera Investor Presentation Deck
As of abstract cutoff date: July 10, 2023
21 patients treated at 5 dose levels with mean 5.8 doses
8 liquid tumors, 13 solid tumors
●
●
●
●
●
KT-333: ASH 2023 Abstract Summary
●
●
SOCIETY
AM
OF
12 evaluable for disease response as of cutoff date
1 CTCL and 1 PTCL patient at DL2 evaluable with one partial response observed in CTCL patient after two
cycles
HEMA
10 solid tumors patients (DL1-4) evaluable, with stable disease observed in 3 patients after two cycles at
DL3 and DL4
Robust dose-dependent target knockdown in DL1-4, with DL3 and beyond at levels associated with anti-
tumor activity in preclinical models
Most common AEs were Grade 1 and 2 constipation, fatigue, nausea and anemia
No drug related SAES or DLTs observed; dose escalation ongoing
Findings support clinical activity with weekly IV infusion
Additional data, including other hematological tumor patients, to be presented during poster session at ASH
Annual Meeting on December 10
KYMERA ©2023 KYMERA THERAPEUTICS, INC.
PAGE 29View entire presentation